APOLLO Oncology Clinical Trials Program

APOLLO Oncology Clinical Trials Program

The APOLLO Oncology Clinical Trials Program is a series of trials evaluating and investigating whether Apollomics’ proprietary assets can work in concert with each other or with other agents to improve single agent immunotherapy response rates, and, ultimately, to confer clinical benefit to patients with cancer.


APOLLO is a Phase 1/2, open label, two-arm, multi-center dose escalation and expansion study targeting locally advanced or metastatic disease.
clinicaltrials.gov: NCT03655613

Agents:           APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Indication:       Hepatocellular Carcinoma

Agents:           APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Indication:       Renal Cell Carcinoma

APOLLO-2 Trial

APOLLO-2 is a planned clinical trial combining APL-101 plus an approved immunotherapy with or without chemotherapy.

Agents:           APL-101 (c-Met inhibitor) + I/O +/- Chemotherapy
Indication:       NSCLC

Posters & Publications

Posters and Publications on our assets can be found here.